Medpace Holdings (MEDP): the CRO stock worth watching

2026-06-28 · By Lubin Danilo, founder of Lubin Investment

Medpace Holdings is an elite CRO that runs clinical trials for pharma and biotech companies, with an integrated model its rivals struggle to copy. It meets 9 of my 10 quality criteria, generates a 25.7% free cash flow margin, and has been buying back its own shares for years. At the current price of $527, my method triggers a buy signal.

What Medpace actually does (and why it is hard)

A pharmaceutical or biotech company has a promising molecule. To get it to market, it needs clinical trials: recruiting patients, following strict protocols, documenting every adverse event, submitting regulatory files to the FDA or the EMA. Enormous work that few companies, especially small biotechs, can handle alone.

That is where a CRO comes in. Medpace handles the entire process, from protocol design to regulatory submission, including pharmacokinetics (how the body absorbs the drug), biostatistics, and medical writing. Everything is done in-house. They call it their one-site model: no outsourcing, everything under one roof.

Why is it hard? Because every clinical trial is unique. A pediatric oncology trial has nothing to do with a cardiovascular trial. You need specialized teams, years of data, and established relationships with regulators. Medpace has built this expertise since 1992, under the leadership of its founder, Dr. August Troendle, a physician by training who still runs the company today. Thirty years of integrated know-how, impossible to copy in two years.

The moat: why switching CRO mid-trial is out of the question

When I look for a durable competitive advantage, I ask a simple question: what would it cost to switch suppliers? In the CRO market, the answer is brutal.

Imagine a lab decides to replace Medpace mid-trial. It would have to transfer millions of patient data points, reaccredit new sites, renegotiate with regulators, risk FDA scrutiny, and lose months, sometimes years, on an already very tight schedule. For a drug where every quarter of delay can cost tens of millions in missed sales, that switch is unthinkable. This is what investors call switching costs: barriers so high they lock in the client well beyond any ordinary commercial relationship.

The second pillar of the moat: specialization. Medpace is particularly strong in biologics, oncology, and rare diseases. These are the most complex, most lucrative, and most regulatory-demanding areas. Labs working in these fields need a partner who knows the pitfalls, not a generalist. Medpace is that specialist.

There is also a financial advantage I particularly like: the payment model. Medpace clients pay a significant portion of contracts upfront. As a result, the company has negative working capital: it collects before it spends. This is a remarkable property. It means that the more Medpace grows, the more cash it automatically generates. This is what drives its Cash ROCE of 563%: for every dollar of capital invested in the business, the company spins out hundreds of dollars of cash.

Quality and score: how I evaluate Medpace

I do not judge a company on instinct. I run it through a grid of 10 fundamental quality criteria, inspired by financial literature (Warren Buffett, Michael Mauboussin, Aswath Damodaran). This grid measures: is it truly profitable, are revenues and cash growing, does it convert accounting profits into real cash, is it lightly indebted, does it return money to shareholders in a disciplined way? I always judge quality separately from price. They are two different questions.

Medpace meets 9 of those 10 criteria. Here are the numbers that speak loudest. Revenue grew 21.9% per year over five years. Free cash flow per share, the money truly available to each shareholder once every bill is paid, grew 33.6% per year over the same period. The free cash flow margin reaches 25.7%: out of every 100 dollars of sales, 25.7 ends up as real cash. The net margin comes in at 17.2%. As for buybacks: the share count shrank 5% per year. Each remaining shareholder owns a growing slice of the company, without doing anything.

One last figure I appreciate: the SBC/FCF ratio, the share of free cash flow absorbed by stock options granted to employees. When this ratio is high, management dilutes shareholders at their expense. At Medpace, it is just 3.2%. Very low. It says something about the culture of the company.

Valuation and current price

Here is the rule I never break: I always separate two questions. One: is this a good company? Two, entirely apart: is this the right price? A great company bought too expensive is still a bad investment. I have answered the first question. Now the second.

To measure the price, I use the P/FCF (price to free cash flow): the share price divided by the cash the company truly generates each year. A P/FCF of 22 means you are paying today the equivalent of twenty-two years of that cash. The lower it is, the cheaper it is. Medpace currently trades at 22.2 times its trailing free cash flow.

My reasonable buy price for Medpace, calculated with deliberately conservative assumptions, comes out at $558.53. The current stock price is $527.07. The stock trades below my threshold: the buy signal is triggered according to my method. This is not a promise of immediate upside, but a price context I consider favorable relative to the quality of the business.

To put this in perspective: major listed CROs like IQVIA or ICON show different profiles, with less consistent growth and more diversified models. Medpace, smaller and more focused, has historically earned a quality premium. Seeing it today at 22 times its free cash flow, against sector averages often higher on less profitable businesses, strikes me as reasonable.

The setup and catalysts to watch

A good business at a good price is the necessary condition. The catalyst is what can unlock the value over a reasonable time horizon.

First catalyst: the pharma and biotech pipeline. Large labs are accelerating development in oncology and rare diseases, two of Medpace's strongholds. Every new molecule in clinical phases is a potential contract. The FDA has also maintained a sustained approval rate in recent years, encouraging labs to keep investing in their pipelines.

Second catalyst: buyback dynamics. Medpace reduces its share count by 5% per year. At this pace, in five years, free cash flow per share will have mechanically grown 25% more than the business itself. A very effective way to create value without relying on external growth.

Next date to watch: the quarterly earnings, where management will comment on the backlog (contracts signed but not yet executed) and new bookings. The Medpace backlog is a leading indicator of upcoming growth. If it keeps growing, the thesis holds.

The risks I won't hide

I would be dishonest to show you only the bright side. Medpace has real risks, and they deserve an honest look.

First risk: biotech cycles. A large portion of Medpace clients are small and mid-size biotechs that depend on venture capital to fund their trials. When interest rates rise or risk appetite falls, biotechs raise less, commission fewer trials, and the Medpace backlog shrinks. This happened in 2023-2024. The company weathered it, but the volatility is real.

Second risk: trial failures or cancellations. A clinical trial can be stopped at any time if interim data disappoints or the sponsor runs out of money. These cancellations hit the backlog and therefore revenue forecasts. Medpace does not control the scientific success of the molecules it tests.

Third risk: competition. IQVIA, ICON, and Syneos are global players with considerable resources. They can cut prices to win contracts, invest in technology, or acquire specialists to erode Medpace's edge. The CRO market is concentrated but intensely competitive.

Fourth and most fundamental risk: quality never protects against overpaying. If you buy the best company in the world at an absurd price, you will make a bad investment. Today, at 22 times free cash flow, Medpace is not screaming cheap. It is a buy signal by my method, not a clearance sale. Price discipline still applies.

My method and how to go further

What I did in this article is what I do for every stock: separate the quality of the business (is the company solid, growing, well managed?) from the price question (is the market selling it to me at a reasonable price?). These two analyses are conducted independently, then crossed. Medpace passes both filters today.

You can find the full criteria breakdown and live data on the Medpace analysis page on our site (/analyse/MEDP). To see how the same method applies to a different sector, check out the Booking analysis (/analyse/BKNG) or explore our methodology guide. My method is always the same: quality first, price second, never the other way around.

Knowing in a few seconds whether a stock is solid and whether its price is reasonable: that is what I wanted to be able to do for any company. So I built it.

FAQ

What is a CRO?

A CRO (contract research organization) is a company that conducts clinical trials on behalf of pharmaceutical or biotech companies. It handles everything: patient recruitment, protocols, data analysis, regulatory submissions. It is a trusted service provider for labs that lack the resources or teams to manage these processes in-house.

How does the 10-criteria quality scoring work?

I run every company through a grid of 10 objective criteria: profitability, revenue growth, free cash flow per share growth, share buybacks, debt level, quality of profit-to-cash conversion, return on capital, absence of structural risk exposure. I judge quality independently from price. Medpace meets 9 criteria out of 10.

What is free cash flow?

Free cash flow is the money that truly stays with the company once all bills and investments are paid. It is harder to dress up than accounting profit, so I rely on it more heavily to judge the real health of a business.

Why is Medpace's Cash ROCE so high?

Cash ROCE measures cash generated relative to capital invested in the business. At Medpace, it is extremely high (563%) because clients pay a portion of contracts upfront: the company has negative working capital. It collects before it spends. The more it grows, the more cash it automatically generates, without needing to tie up additional capital.

What are the main risks of Medpace?

Three main risks: dependence on biotech funding cycles (if venture capital dries up, orders fall); trial cancellations that Medpace does not control; and competition from IQVIA, ICON, and Syneos who have significant resources. This is not investment advice, do your own research.

Voir l'analyse MEDP sur Lubin Investment

About the author

Written by Lubin Danilo, founder of Lubin Investment. A self-taught individual investor, I find fundamental analysis fascinating, and it has delivered excellent results. For three years now, my performance has beaten the S&P 500. But analyzing every stock took too much time: sites with incomplete data, calculation methods and criteria never aligned with mine. And spotting the best stocks was just as time-consuming, even with my own well-defined checklist. So I put my software development background to work to build this software, base my investment strategy on its results, and share it with people who share the same passion as me. It judges a company's quality and its price separately, using criteria drawn from the financial literature (Warren Buffett, Michael Mauboussin, Aswath Damodaran).